GHB and synthetic cathinones: clinical effects and potential consequences.
Laurent Karila, Michel Reynaud
Drug Testing and Analysis September 2011 DOI: 10.1002/dta.210 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Key findings | The authors report that GHB and synthetic cathinones can produce negative health and social consequences in recreational and chronic users, that their addictive potential is not weak, and that non-fatal overdoses and deaths have been reported. They caution that GBL and synthetic cathinones are sold as substitutes for GHB and MDMA, respectively, and argue for prevention and harm-reduction interventions on the Internet and in recreational settings. |
Abstract
Designer drugs belong to a group of legally or illegally produced substances that are structurally and pharmacologically very similar to illicit drugs. In the past, designer drugs were often used during all-night dance parties, but they are now consumed in multiple settings from college bars to parks to private house parties. Most of these club drugs can be bought on legal websites and home-delivered for private parties. Recently, legal highs have once again become a burning media issue across the world. Our review will focus on GHB and synthetic cathinones. Literature searches were conducted for the period from 1975 to July 2010 using PubMed, EMBASE, PsycInfo, Internet underground and governmental websites using the following keywords alone or in combination: designer drugs, club drugs, party drugs, GHB, synthetic cathinones, mephedrone, methylone, flephedrone, MDAI, and MDVP. Available epidemiological, neurobiological, and clinical data for each compound are described. There is evidence that negative health and social consequences may occur in recreational and chronic users. The addictive potential of designer drugs is not weak. Non-fatal overdoses and deaths related to GHB/GBL or synthetic cathinones have been reported. Clinicians must be careful with GBL or synthetic cathinones, which are being sold and used as substitutes for GHB and MDMA, respectively. Interventions for drug prevention and harm reduction in response to the use of these drugs should be implemented on the Internet and in recreational settings. Prevention, Information, Action, and Treatment are the main goals that must be addressed for this new potentially addictive problem.
Citations in the library
Cited by 11
- Modulation of Social Cognition via Hallucinogens and “Entactogens” Frontiers in Psychiatry December 3, 2019
- Novel Psychoactive Substances—Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs Frontiers in Psychiatry August 18, 2017
- The effects and toxicity of cathinones from the users' perspectives: A qualitative study. Human Psychopharmacology: Clinical and Experimental May 1, 2017
- Focus on Adolescent Use of Club Drugs and "Other" Substances. Pediatric Clinics of North America December 1, 2019
- 5-Iodo-2-aminoindan (5-IAI): chemistry, pharmacology, and toxicology of a research chemical producing MDMA-like effects. Toxicology Letters March 27, 2013
and 6 more in the library
Cites 8
- Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens Journal of Psychoactive Drugs October 1, 1986
- Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate American Journal of Health-System Pharmacy June 1, 2002
- Metabolism of designer drugs of abuse: an updated review. Current Drug Metabolism June 1, 2010
- Combined intoxication with methylone and 5-MeO-MIPT Progress in Neuro-Psychopharmacology and Biological Psychiatry July 30, 2006
- Deaths associated with MBDB misuse. International Journal of Legal Medicine 2000
and 3 more in the library